Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | IDH2 | P48735 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363002 | 1.00 | KMT2A (0.52) | KMT2ATDP1IDH2MAPTTP53 | |
| SCHEMBL7195977 | 0.97 | KMT2A (0.49) | KMT2ATDP1IDH2MAPTTP53 | |
| SCHEMBL7195979 | 0.97 | KMT2A (0.49) | KMT2ATDP1IDH2MAPTTP53 | |
| SCHEMBL5366825 | 0.87 | STS (0.45) | KMT2ATDP1MAPTTP53POLB | |
| SCHEMBL5366823 | 0.87 | STS (0.45) | KMT2ATDP1MAPTTP53POLB | |
| SCHEMBL5374719 | 0.87 | CA1 (0.42) | KMT2ATDP1MAPTTP53LMNA | |
| SCHEMBL5374726 | 0.87 | CA1 (0.42) | KMT2ATDP1MAPTTP53LMNA | |
| SCHEMBL5371190 | 0.85 | KMT2A (0.42) | KMT2ATDP1IDH2MAPTTP53 | |
| SCHEMBL5371185 | 0.85 | KMT2A (0.42) | KMT2ATDP1IDH2MAPTTP53 | |
| SCHEMBL6599031 | 0.85 | KMT2A (0.48) | KMT2ATDP1IDH2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | claimed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | claimed |
| US-7282592-B2 | Resorcinol derivatives | WARNER-LAMBERT COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070122367-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7173052-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | BRADLEY STUART E | 2005-12-22 | — | — | US | disclosed |
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122367-A1 | RESORCINOL DERIVATIVES | LRAT, NQO1, ALDH1A2 | KMT2A 2259/4885TDP1 3111/4885IDH2 2192/4885 |
| US-20030180236-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | KMT2A 2259/4885TDP1 3111/4885IDH2 2192/4885 |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | RBP4, NQO1, ALDH1A2 | KMT2A 771/4885TDP1 3548/4885IDH2 2442/4885 |
| US-20020114770-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | KMT2A 2259/4885TDP1 3111/4885IDH2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.